Notice of Annual General Meeting/Proxy Form
Released
Released
Announcement PDF
Emyria Limited
ACN 625 085 734
Notice of Annual General Meeting
The Annual General Meeting of the Company will be held as follows:
Time and date:
9.00am (AWST) on Thursday, 16 November 2023
Location:
At the offices of Stantons International, Level 2, 40 Kings Park Road,
West Perth, WA, Australia
The Notice of Annual General Meeting should be read in its entirety.
If Shareholders are in doubt as to how to vote, they should seek advice from their suitably
qualified advisor prior to voting.
Should you wish to discuss any matter, please do not hesitate to contact the Company on
+61 (8) 6559 2800.
Shareholders are urged to vote by lodging the Proxy Form
Emyria Limited
ACN 625 085 734
(Company)
Notice of Annual General Meeting
Notice is hereby given that the annual general meeting of Shareholders of Emyria Limited (Company) will be
held at the offices of Stantons International, Level 2, 40 Kings Park Road, West Perth, WA, Australia on
Thursday, 16 November 2023 at 9.00am (AWST) (Meeting).
The Explanatory Memorandum provides additional information on matters to be considered at the Meeting.
The Explanatory Memorandum and the Proxy Form are included as part of the Notice.
The Directors have determined pursuant to regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that
the persons eligible to vote at the Meeting are those who are registered as Shareholders on Tuesday, 14
November 2023 at 4.00pm (AWST).
Terms and abbreviations used in the Notice are defined in Schedule 1.
Agenda
1
Annual Report
To consider the Annual Report of the Company and its controlled entities for the financial year ended
30 June 2023, which includes the Financial Report, the Directors' Report and the Auditor's Report.
Note: there is no requirement for Shareholders to approve the Annual Report.
2
Resolutions
Resolution 1 – Remuneration Report
To consider and, if thought fit, to pass with or without amendment, as a non-binding ordinary resolution
the following:
'That, the Remuneration Report be adopted by Shareholders, on the terms and conditions in the
Explanatory Memorandum.'
Note: a vote on this Resolution is advisory only and does not bind the Directors or the Company.
Resolution 2 – Election of Director – Dr Mohit Kaushal
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the
following:
‘That, Dr Mohit Kaushal, who retires in accordance with Article 7.6(c) of the Constitution, Listing Rule
14.4 and for all other purposes, retires and, being eligible and offering himself for election, is elected as
a director, on the terms and conditions in the Explanatory Memorandum.’
Page 2
Resolution 3 – Re-election of Director – Sir John Tooke
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the
following:
‘That, Sir John Tooke, who retires in accordance with Article 7.2(a) of the Constitution, Listing Rule 14.4
and for all other purposes, retires and, being eligible and offering himself for re-election, is re-elected
as a director, on the terms and conditions in the Explanatory Memorandum.’
Resolution 4 – Approval of 10% Placement Facility
To consider and, if thought fit, to pass with or without amendment, as a special resolution the
following:
'That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders
approve the issue of Equity Securities totalling up to 10% of the issued capital of the Company at the
time of issue, calculated in accordance with the formula prescribed in Listing Rule 7.1A.2, on the
terms and conditions in the Explanatory Memorandum.'
Resolution 5 – Ratification of issue of May 2023 Placement Securities
To consider and, if thought fit, to pass with or without amendment, each as a separate ordinary
resolution the following:
'That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of
33,333,332 Placement Securities as follows:
(a)
16,666,666 Placement Options issued under Listing Rule 7.1; and
(b)
16,666,666 Placement Shares issued under Listing Rule 7.1A,
on the terms and conditions in the Explanatory Memorandum.’
Resolution 6 – Ratification of issue of Pax Consideration Shares
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the
following:
‘That, pursuant to and in accordance with Listing Rule 7.4, and for all other purposes, Shareholders
ratify the issue of 10,236,220 Pax Consideration Shares under Listing Rule 7.1, on the terms and
conditions in the Explanatory Memorandum.’
3
Voting prohibitions
Resolution 1: In accordance with sections 250BD and 250R of the Corporations Act, a vote on this
Resolution must not be cast (in any capacity) by or on behalf of a member of the Key Management
Personnel details of whose remuneration are included in the Remuneration Report, or a Closely Related
Party of such a member.
A vote may be cast by such person if the vote is not cast on behalf of a person who is excluded from
voting on this Resolution, and:
Page 3
4
(a)
the person is appointed as a proxy by writing that specifies the way the proxy is to vote on this
Resolution; or
(b)
the voter is the Chair and the appointment of the Chair as proxy does not specify the way the
proxy is to vote on this Resolution, but expressly authorises the Chair to exercise the proxy
even if this Resolution is connected with the remuneration of a member of the Key Management
Personnel.
Voting exclusions
Pursuant to the Listing Rules, the Company will disregard any votes cast in favour of:
Resolution 4: if at the time of the Meeting, the Company is proposing to make an issue of Equity
Securities under Listing Rule 7.1A.2, by or on behalf of any persons who are expected to participate in,
or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason
of being a Shareholder), or any of their respective associates.
Resolution 5(a) and (b): by or on behalf of Tattarang Tenmile Ventures, Sixty Two Capital Pty Ltd and
any other person who participated in the issue of the Placement Securities, or any of their respective
associates, or their nominees.
Resolution 6: by or on behalf of Glenroy WA Pty Ltd and Vivo (WA) Pty Ltd or any other person who
participated in the issue, or any of their respective associates, or their nominees.
The above voting exclusions do not apply to a vote cast in favour of the relevant Resolution by:
(a)
a person as proxy or attorney for a person who is entitled to vote on the Resolution, in
accordance with directions given to the proxy or attorney to vote on the Resolution in that way;
(b)
the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in
accordance with a direction given to the Chair to vote on the Resolution as the Chair decides;
or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a
beneficiary provided the following conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the beneficiary is not
excluded from voting, and is not an associate of a person excluded from voting, on the
Resolution; and
(ii)
the holder votes on the Resolution in accordance with directions given by the
beneficiary to the holder to vote in that way.
BY ORDER OF THE BOARD
Susan Park
Company Secretary
Emyria Limited
Dated: 13 October 2023
Page 4
Emyria Limited
ACN 625 085 734
(Company)
Explanatory Memorandum
1.
Introduction
The Explanatory Memorandum has been prepared for the information of Shareholders in
connection with the business to be conducted at the Meeting to be held at the offices of Stantons
International, Level 2, 40 Kings Park Road, West Perth, WA, Australia on Thursday, 16
November 2023 at 9.00am (AWST).
The Explanatory Memorandum forms part of the Notice which should be read in its entirety. The
Explanatory Memorandum contains the terms and conditions on which the Resolution will be
voted.
The Explanatory Memorandum includes the following information to assist Shareholders in
deciding how to vote on the Resolutions:
Section 2
Action to be taken by Shareholders
Section 3
Annual Report
Section 4
Resolution 1 – Remuneration Report
Section 5
Resolution 2 – Election of Director – Dr Mohit Kaushal
Section 6
Resolution 3 – Re-election of Director – Sir John Tooke
Section 7
Resolution 4 – Approval of 10% Placement Facility
Section 8
Resolution 5 – Ratification of issue of May 2023 Placement Securities
Section 9
Resolution 6 – Ratification of issue of Pax Consideration Shares
Schedule 1
Definitions
Schedule 2
Terms and conditions of Placement Options
A Proxy Form is enclosed with the Notice of Annual General Meeting.
Page 5
2.
Action to be taken by Shareholders
Shareholders should read the Notice including the Explanatory Memorandum carefully before
deciding how to vote on the Resolutions.
Voting on all proposed Resolutions at the Meeting will be conducted by poll. On a poll, each
Shareholder has one vote for every fully paid ordinary Share held in the Company.
2.1
Voting in person
To vote in person, attend the Meeting on the date and at the place set out above.
2.2
Voting by a corporation
A Shareholder that is a corporation may appoint an individual to act as its representative and
vote in person at the Meeting. The appointment must comply with the requirements of section
250D of the Corporations Act. The representative should bring to the Meeting evidence of his
or her appointment, including any authority under which it is signed.
2.3
Voting by proxy
Shareholders are encouraged to vote by completing a Proxy Form.
A Proxy Form is enclosed with the Notice. This is to be used by Shareholders if they wish to
appoint a representative (a 'proxy') to vote in their place. All Shareholders are invited and
encouraged to attend the Meeting or, if they are unable to attend in person, sign and return the
Proxy Form to the Company in accordance with the instructions thereon. Lodgement of a Proxy
Form will not preclude a Shareholder from attending and voting at the Meeting in person.
Please note that:
(a)
a member of the Company entitled to attend and vote at the Meeting is entitled to
appoint a proxy;
(b)
a proxy need not be a member of the Company; and
(c)
a member of the Company entitled to cast two or more votes may appoint two proxies
and may specify the proportion or number of votes each proxy is appointed to exercise,
but where the proportion or number is not specified, each proxy may exercise half of
the votes.
The enclosed Proxy Form provides further details on appointing proxies and lodging Proxy
Forms.
Section 250BB(1) of the Corporations Act provides that an appointment of a proxy may specify
the way the proxy is to vote on a particular resolution and, if it does:
(a)
the proxy need not vote on a show of hands, but if the proxy does so, the proxy must
vote that way (i.e. as directed);
(b)
if the proxy has 2 or more appointments that specify different ways to vote on the
resolution – the proxy must not vote on a show of hands;
(c)
if the proxy is the Chair of the meeting at which the resolution is voted on – the proxy
Page 6
must vote on a poll, and must vote that way (i.e. as directed); and
(d)
if the proxy is not the Chair – the proxy need not vote on the poll, but if the proxy does
so, the proxy must vote that way (i.e. as directed).
Section 250BC of the Corporations Act provides that, if:
(a)
an appointment of a proxy specifies the way the proxy is to vote on a particular resolution
at a meeting of the Company's members;
(b)
the appointed proxy is not the chair of the meeting;
(c)
at the meeting, a poll is duly demanded, or is otherwise required under section 250JA
on the resolution; and
(d)
either the proxy is not recorded as attending the meeting or the proxy does not vote on
the resolution,
the Chair of the meeting is taken, before voting on the resolution closes, to have been appointed
as the proxy for the purposes of voting on the resolution at the meeting.
Your proxy voting instruction must be received by 9.00am (AWST) on Tuesday, 14 November
2023, being not later than 48 hours before the commencement of the Meeting.
2.4
Chair's voting intentions
If the Chair is your proxy, either by appointment or by default, and you have not indicated your
voting intention, you expressly authorise the Chair to exercise the proxy in respect of
Resolution 1 even though this Resolution is connected directly or indirectly with the
remuneration of the Company's Key Management Personnel.
The Chair intends to exercise all available proxies in favour of all Resolutions, unless the
Shareholder has expressly indicated a different voting intention.
2.5
Submitting questions
Shareholders will also have the opportunity to submit questions during the Meeting in respect
to the formal items of business. In order to ask a question during the Meeting, please follow the
instructions from the Chair.
The Chair will attempt to respond to the questions during the Meeting. The Chair will request
prior to a Shareholder asking a question that they identify themselves (including the entity name
of their shareholding and the number of Shares they hold).
3.
Annual Report
In accordance with section 317 of the Corporations Act, Shareholders will be offered the
opportunity to discuss the Annual Report, including the Financial Report, the Directors' Report
and the Auditor's Report for the financial year ended 30 June 2023.
There is no requirement for Shareholders to approve the Annual Report.
At the Meeting, Shareholders will be offered the opportunity to:
Page 7
(a)
discuss the Annual Report which is available online at https://emyria.com/;
(b)
ask questions about, or comment on, the management of the Company; and
(c)
ask the auditor questions about the conduct of the audit and the preparation and content
of the Auditor's Report.
In addition to taking questions at the Meeting, written questions to the Chair about the
management of the Company, or to the Company's auditor about:
(a)
the preparation and content of the Auditor's Report;
(b)
the conduct of the audit;
(c)
accounting policies adopted by the Company in relation to the preparation of the
financial statements; and
(d)
the independence of the auditor in relation to the conduct of the audit,
may be submitted no later than five business days before the Meeting to the Company Secretary
at the Company's registered office.
The Company will not provide a hard copy of the Company’s Annual Report to Shareholders
unless specifically requested to do so.
4.
Resolution 1 – Remuneration Report
4.1
General
In accordance with section 250R(2) of the Corporations Act, the Company must put the
Remuneration Report to the vote of Shareholders. The Directors' Report for the year ended
30 June 2023 in the 2023 Annual Report contains the Remuneration Report which sets out the
remuneration policy for the Company and the remuneration arrangements in place for specified
executives and non-executive Directors.
In accordance with section 250R(3) of the Corporations Act, Resolution 1 is advisory only and
does not bind the Directors. If Resolution 1 is not passed, the Directors will not be required to
alter any of the arrangements in the Remuneration Report.
If the Company's Remuneration Report receives a 'no' vote of 25% or more (Strike) at two
consecutive annual general meetings, Shareholders will have the opportunity to remove the
whole Board, except the Managing Director (if any).
Where a resolution on the Remuneration Report receives a Strike at two consecutive annual
general meetings, the Company will be required to put to Shareholders at the second annual
general meeting a resolution on whether another meeting should be held (within 90 days) at
which all Directors (other than the managing director, if any) who were in office at the date of
approval of the applicable Directors' Report must stand for re-election.
The Company's Remuneration Report did not receive a Strike at the 2022 annual general
meeting. If the Remuneration Report receives a Strike at this Meeting, Shareholders should be
aware that if a second Strike is received at the 2024 annual general meeting, this may result in
the re-election of the Board.
Page 8
The Chair will allow a reasonable opportunity for Shareholders as a whole to ask about or make
comments on the Remuneration Report.
4.2
Additional information
Resolution 1 is an ordinary resolution.
Given the personal interests of all Directors in the outcome of this Resolution, the Board declines
to make a recommendation to Shareholders regarding this Resolution.
5.
Resolution 2 – Election of Director – Dr Mohit Kaushal
5.1
General
Article 7.6(a) of the Constitution provides that the Directors may at any time appoint any person
to be a Director, either to fill a casual vacancy or as an addition to the existing Directors.
Article 7.6(c) of the Constitution and Listing Rule 14.4 both provide that a Director appointed to
fill a casual vacancy or as an addition to the existing Directors holds office until the conclusion
of the next annual general meeting of the Company but is eligible for election at that meeting.
Dr Mohit Kaushal, Non-Executive Director, was appointed as a Director on 21 August 2023.
Accordingly, Dr Mohit Kaushal retires at this Meeting and, being eligible, seeks election pursuant
to this Resolution 2.
If Resolution 2 is passed, Dr Mohit Kaushal will be elected as a Director of the Company with
effect from the conclusion of the Meeting.
If Resolution 2 is not passed, Dr Mohit Kaushal will not be elected as a Director of the Company.
5.2
Dr Mohit Kaushal
Dr Mohit Kaushal is an Adjunct Professor at Stanford University within the Biomedical Data
Science Department. Dr Mohit Kaushal continues to be active within public policy and is a
Scholar in Residence at the Duke Margolis Centre for Health Policy. He was previously a Visiting
Scholar at the Brookings Institution. He has also been appointed to the FDASIA Workgroup of
the Health IT Policy Committee and to the National Committee on Vital and Health Statistics,
advising HHS on Data Access and Use.
Dr Mohit Kaushal also built and led the first dedicated health care team at the Federal
Communications Commission, where his team initiated collaboration with the Food and Drug
Administration (FDA) for the regulatory streamlining of converged telecommunications, data
analytics and medical devices leading to the release of the mobile medical applications guidance
by the FDA. In addition, his team reformed the Rural Healthcare fund to create the Healthcare
Connect Fund, which aligned the funding mechanism with wider health care payment policy and
technology reform.
Dr Mohit Kaushal’s noteworthy affiliations encompass roles at Humedica (acquired by Optum
Health), Rxante (acquired by Millennium), Change Healthcare (acquired by Emdeon), Universal
American (NYSE:UAM) acquired by WellCare (NYSE: WCG), CitiusTech (acquired by Baring),
Gravie, Insight Psychiatry, Wellframe (acquired by HealthEdge), Elation Health, The Oncology
Institute (NASDAQ:TOI) and Oak Street Health (NYSE:OSH).
Page 9
Dr Mohit Kaushal does not currently hold any other material directorships, other than as
disclosed in this Notice.
The Company confirms that it took appropriate checks into Dr Mohit Kaushal’s background and
experience and that these checks did not identify any information of concern.
If elected, Dr Mohit Kaushal is considered by the Board (with Dr Mohit Kaushal abstaining) to
be an independent Director. Dr Mohit Kaushal is not considered by the Board to hold any
interest, position or relationship that might influence, or reasonably be perceived to influence, in
a material respect his capacity to bring an independent judgement to bear on issues before the
Board and to act in the best interests of the entity as a whole rather than in the interests of an
individual security holder or other party.
Dr Mohit Kaushal has acknowledged to the Company that he will have sufficient time to fulfil his
responsibilities as a Director.
5.3
Board recommendation
The Board (with Dr Mohit Kaushal abstaining) supports the election of Dr Mohit Kaushal.
Dr Mohit Kaushal’s skills and significant experience as a renowned figure in clinical
transformation and digital health enhances the Board’s capability.
5.4
Additional information
Resolution 2 is an ordinary resolution.
6.
Resolution 3 – Re-election of Director – Sir John Tooke
6.1
General
Article 7.2(a) of the Constitution and Listing Rule 14.4 both provide that a Director (excluding
the Managing Director) must not hold office without re-election past the third annual general
meeting following that Director's appointment, last election or three years, whichever is longer.
Article 7.3 of the Constitution provides that a Director who retires in accordance with Article
7.2(a) of the Constitution is eligible for re-election and that re-election takes effect at the
conclusion of the Meeting.
Sir John Tooke, Non-Executive Director, was last elected at the 2020 annual general meeting
of the Company. Accordingly, Sir John Tooke retires at this Meeting and, being eligible, seeks
re-election pursuant to this Resolution 3.
6.2
Sir John Tooke
Sir John Tooke is Executive Chairman of Academic Health Solutions, a start-up Group offering
international expert advice to clients on medical research, innovation strategy, and health
service transformation. He is Senior Independent Director at BUPA Chile and was, until 2019,
non-executive director of the BUPA main Board and the Chair of the Medical Advisory Council.
He is a non-executive director of the Northern Health Science Alliance in the UK. He is the Chair
of Collaboration for the Advancement of Sustainable Medical Innovation (CASMI), UCL Partners
and Chaired the Oversight Group for the Academy of Medical Sciences project, “How we best
Page 10
use scientific evidence to judge the benefits and harms of medicines”. He also served as an
Independent Review Board Member for Google DeepMind Health (UK).
Sir John Tooke was past Head of the School of Life and Medical Sciences at University College
London (UCL) as Vice Provost (Health) and Academic Director of UCL Partners from 2010 2015. He was also the former President of the Academy of Medical Sciences in the UK. Sir John
is a clinician scientist with 30 years of experience as a consultant physician specialising in
diabetes, endocrinology, vascular medicine and internal medicine with broad research
experience (basic biomedical, experimental medicine, and applied health research, including
improvement science) recognised through Fellowship of the Academy of Medical Sciences. He
held a Board position at the Francis Crick Institute (2011-2015) and was a Member of the
Council for Science & Technology (2011-2015), reporting to the Prime Minister (UK).
Sir John Tooke does not currently hold any other material directorships, other than as disclosed
in this Notice.
If re-elected, Sir John Tooke is considered by the Board (with Sir John Tooke abstaining) to be
an independent Director. Sir John Tooke is not considered by the Board to hold any interest,
position or relationship that might influence, or reasonably be perceived to influence, in a
material respect his capacity to bring an independent judgement to bear on issues before the
Board and to act in the best interests of the entity as a whole rather than in the interests of an
individual security holder or other party.
Sir John Tooke has acknowledged to the Company that he will have sufficient time to fulfil his
responsibilities as a Director.
6.3
Board recommendation
The Board (with Sir John Tooke abstaining) supports the re-election of Sir John Tooke.
Sir John Tooke’s skills and significant experience in sector in which the Company operates
bolsters the Board’s capability.
6.4
Additional information
Resolution 3 is an ordinary resolution.
7.
Resolution 4 – Approval of 10% Placement Facility
7.1
General
Listing Rule 7.1A enables an eligible entity to issue Equity Securities up to 10% of its issued
share capital through placements over a 12-month period after the annual general meeting (10%
Placement Facility). The 10% Placement Facility is in addition to the Company's 15% annual
placement capacity under Listing Rule 7.1.
Resolution 4 seeks Shareholder approval to provide the Company with the ability to issue Equity
Securities under the 10% Placement Facility during the 10% Placement Period (refer to Section
7.2(f) below). The number of Equity Securities to be issued under the 10% Placement Facility
will be determined in accordance with the formula prescribed in Listing Rule 7.1A.2 (refer to
Section 7.2(c) below).
If Resolution 4 is passed, the Company will be able to issue Equity Securities up to the combined
25% limit in Listing Rules 7.1 and 7.1A without any further Shareholder approval.
Page 11
If Resolution 4 is not passed, the Company will not be able to access the additional 10% capacity
to issue Equity Securities without Shareholder approval provided for in Listing Rule 7.1A and
will remain subject to the 15% limit on issuing Equity Securities without Shareholder approval in
Listing Rule 7.1.
7.2
Listing Rule 7.1A
(a)
Is the Company an eligible entity?
An eligible entity for the purposes of Listing Rule 7.1A is an entity that is not included in
the S&P/ASX 300 Index and has a market capitalisation of $300 million or less.
The Company is an eligible entity as it is not included in the S&P/ASX 300 Index and
has a market capitalisation of approximately $25.15 million, based on the closing price
of Shares ($0.07) on 9 October 2023.
(b)
What Equity Securities can be issued?
Any Equity Securities issued under the 10% Placement Facility must be in the same
class as an existing quoted class of Equity Securities of the eligible entity.
As at the date of this Notice, the Company has on issue one quoted class of Equity
Securities, being Shares.
(c)
How many Equity Securities can be issued?
Listing Rule 7.1A.2 provides that under the approved 10% Placement Facility, the
Company may issue or agree to issue a number of Equity Securities calculated in
accordance with the following formula:
(A x D) – E
Where:
A=
is the number of Shares on issue at the commencement of the Relevant Period:
(A)
plus the number of fully paid shares issued in the Relevant Period under
an exception in Listing Rule 7.2 other than exception 9, 16 or 17;
(B)
plus the number of fully paid shares issued in the Relevant Period on
the conversion of convertible securities within Listing Rule 7.2 exception
9 where:
(C)
(1)
the convertible securities were issued or agreed to be issued
before the commencement of the Relevant Period; or
(2)
the issue of, or agreement to issue, the convertible securities
was approved, or taken under the Listing Rules to have been
approved, under Listing Rule 7.1 or Listing Rule 7.4;
plus the number of fully paid shares issued in the Relevant Period under
an agreement to issue securities within Listing Rule 7.2 exception 16
where:
Page 12
(1)
the agreement was entered into before the commencement of
the Relevant Period; or
(2)
the agreement or issue was approved, or taken under the
Listing Rules to have been approved, under Listing Rule 7.1 or
Listing Rule 7.4;
(D)
plus the number of partly paid shares that became fully paid shares in
the Relevant Period;
(E)
plus the number of fully paid shares issued in the Relevant Period with
approval under Listing Rules 7.1 and 7.4; and
(F)
less the number of fully paid shares cancelled in the Relevant Period.
Note that ‘A’ has the same meaning in Listing Rule 7.1 when calculating the
Company’s 15% annual placement capacity.
(d)
D=
is 10%.
E=
is the number of Equity Securities issued or agreed to be issued under Listing
Rule 7.1A.2 in the 12 months before the date of the issue or agreement to issue,
where the issue or agreement has not been subsequently approved by
Shareholders under Listing Rule 7.4.
What is the interaction with Listing Rule 7.1?
The Company’s ability to issue Equity Securities under Listing Rule 7.1A will be in
addition to its 15% annual placement capacity under Listing Rule 7.1.
(e)
At what price can the Equity Securities be issued?
Any Equity Securities issued under Listing Rule 7.1A must be issued for a cash
consideration per Equity Security which is not less than 75% of the VWAP of Equity
Securities in the same class calculated over the 15 Trading Days on which trades in
that class were recorded immediately before:
(f)
(i)
the date on which the price at which the Equity Securities are to be issued is
agreed by the Company and the recipient of the Equity Securities; or
(ii)
if the Equity Securities are not issued within 10 Trading Days of the date in
paragraph 7.2(e)(i) above, the date on which the Equity Securities are issued,
(Minimum Issue Price).
When can Equity Securities be issued?
Shareholder approval of the 10% Placement Facility under Listing Rule 7.1A will be valid
from the date of the Meeting and will expire on the earlier of:
(i)
the date that is 12 months after the date of the Meeting;
(ii)
the time and date of the Company's next annual general meeting; or
Page 13
(iii)
the time and date of Shareholder approval of a transaction under Listing Rules
11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal
of main undertaking),
(10% Placement Period).
(g)
What is the effect of Resolution 4?
The effect of Resolution 4 will be to allow the Company to issue the Equity Securities
under Listing Rule 7.1A during the 10% Placement Period without further Shareholder
approval or using the Company's 15% annual placement capacity under Listing
Rule 7.1.
7.3
Specific information required by Listing Rule 7.3A
Pursuant to and
Share your feedback
Discover